Guggenheim Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $75

Guggenheim analyst Seamus Fernandez maintains Bristol-Myers Squibb (NYSE:BMY) with a Buy and raises the price target from $72 to $75.